GlassScriptPhysician profile
Wesley G Patterson
NPI 1295127504
$19,114.99
in general payments reported to CMS, 2019-2025
14 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $336 · 2022: $7,088 · 2023: $4,045 · 2024: $6,293 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,396 · Food and Beverage: $2,784 · Travel and Lodging: $2,399 · Honoraria: $2,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,396.00 |
| Food and Beverage | $2,783.76 |
| Travel and Lodging | $2,398.84 |
| Honoraria | $2,112.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $9,480.70 | 2022-2025 | |
| Horizon Therapeutics Plc | $7,203.96 | 2021-2023 | Ravicti |
| Alexion Pharmaceuticals, INC. | $693.37 | 2023-2025 | Koselugo |
| Biomarin Pharmaceutical INC. | $584.23 | 2021-2025 | Palynziq, Voxzogo 1.2mg |
| Ptc Therapeutics, INC. | $318.52 | 2021-2025 | Sephience |
| Chiesi USA, INC. | $133.67 | 2023-2025 | Elfabrio, Lamzede |
| Neurocrine Biosciences, INC. | $126.57 | 2025 | |
| Amgen INC. | $125.00 | 2024 | Ravicti |
| Illumina, INC. | $122.99 | 2024 | Genetic Disease Testing |
| Pharming Healthcare, INC. | $122.93 | 2024 | |
| Amicus Therapeutics, INC. | $101.61 | 2024 | Pombiliti, Opfolda, Galafold |
| Soleno Therapeutics, INC. | $43.05 | 2025 | Vykat Xr |
| Zevra Therapeutics INC | $43.04 | 2025 | Olpruva |
| Depuy Synthes Sales INC. | $15.35 | 2024 | Monovisc, Orthovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.